Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$2.41 USD
+0.01 (0.30%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $2.42 +0.01 (0.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANEB 2.41 +0.01(0.30%)
Will ANEB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANEB based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ANEB
Anebulo Pharmaceuticals (ANEB) Downgraded by Maxim Analyst | ANEB Stock News
Maxim gets more bearish on Anebulo Pharmaceuticals, downgrades shares
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
12 Health Care Stocks Moving In Wednesday's Intraday Session
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings